353 related articles for article (PubMed ID: 31628043)
21. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
22. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Ettl J; Quek RGW; Lee KH; Rugo HS; Hurvitz S; Gonçalves A; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Markova D; Bhattacharyya H; Hannah AL; Eiermann W; Blum JL; Litton JK
Ann Oncol; 2018 Sep; 29(9):1939-1947. PubMed ID: 30124753
[TBL] [Abstract][Full Text] [Related]
23. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30): validation of English version in Singapore.
Luo N; Fones CS; Lim SE; Xie F; Thumboo J; Li SC
Qual Life Res; 2005 May; 14(4):1181-6. PubMed ID: 16041912
[TBL] [Abstract][Full Text] [Related]
24. The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry.
Husson O; de Rooij BH; Kieffer J; Oerlemans S; Mols F; Aaronson NK; van der Graaf WTA; van de Poll-Franse LV
Oncologist; 2020 Apr; 25(4):e722-e732. PubMed ID: 32297435
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
Van Cutsem E; Amonkar M; Fuchs CS; Alsina M; Özgüroğlu M; Bang YJ; Chung HC; Muro K; Goekkurt E; Benson AB; Sun W; Wainberg ZA; Norquist JM; Chen X; Shih CS; Shitara K
Gastric Cancer; 2021 Nov; 24(6):1330-1340. PubMed ID: 34363528
[TBL] [Abstract][Full Text] [Related]
26. Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study.
Lu Z; Kong L; Wang B; Wang J; Liu L; Shu Y; Yang L; Sun G; Cao G; Ji Y; Cui T; Liu H; Qiu W; Li N; Li G; Luo H; Hou X; Zhang Y; Yue W; Xue L; Liu Z; Pan Y; Gao S; Wang X; Pan Z; Zhang S; Lin G; Xie Y; Gu K; Ren T; Li W; Li T; Wang S; He W; Fan Y; Liang J; Xia B; Zhao L; Wang S; Shen L
EClinicalMedicine; 2024 Jun; 72():102623. PubMed ID: 38800802
[TBL] [Abstract][Full Text] [Related]
27. The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30.
Guzelant A; Goksel T; Ozkok S; Tasbakan S; Aysan T; Bottomley A
Eur J Cancer Care (Engl); 2004 May; 13(2):135-44. PubMed ID: 15115469
[TBL] [Abstract][Full Text] [Related]
28. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.
Schmid P; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Mejia JA; Zhou X; Haiderali A; Nguyen AM; Cortes J; Winer EP
Eur J Cancer; 2023 Dec; 195():113393. PubMed ID: 37976633
[TBL] [Abstract][Full Text] [Related]
29. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.
Lorusso D; Colombo N; Herraez AC; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay SE; Ray-Coquard IL; Shapira-Frommer R; Kim YM; McCormack M; Massaad R; Nguyen AM; Zhao Q; McKenzie J; Prabhu VS; Makker V
Eur J Cancer; 2023 Jun; 186():172-184. PubMed ID: 37086595
[TBL] [Abstract][Full Text] [Related]
30. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümüş M; Laktionov K; Hermes B; Cicin I; Rodríguez-Cid J; Wilson J; Kato T; Ramlau R; Novello S; Reddy S; Kopp HG; Piperdi B; Li X; Burke T; Paz-Ares L
J Clin Oncol; 2020 Jan; 38(3):271-280. PubMed ID: 31751163
[TBL] [Abstract][Full Text] [Related]
31. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.
Tabernero J; Alsina M; Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Ando T; Yalçın Ş; Van Cutsem E; Sabater J; Skanji D; Leger C; Amellal N; Ilson DH
Gastric Cancer; 2020 Jul; 23(4):689-698. PubMed ID: 32128634
[TBL] [Abstract][Full Text] [Related]
32. Baseline functioning scales of EORTC QLQ-C30 predict overall survival in patients with gastrointestinal cancer: a meta-analysis.
Zang Y; Qiu Y; Sun Y; Fan Y
Qual Life Res; 2024 Jun; 33(6):1455-1468. PubMed ID: 38227073
[TBL] [Abstract][Full Text] [Related]
33. A brief instrument to measure health-related quality-of-life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-QoL-10).
Marschner N; Wilke J; Reschke D; Kaiser F; Schmoor C; Grugel R; Boller E
J Med Econ; 2018 Sep; 21(9):920-929. PubMed ID: 29874105
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
Khattak MA; Luke JJ; Long GV; Ascierto PA; Rutkowski P; Schadendorf D; Robert C; Grob JJ; de la Cruz Merino L; Del Vecchio M; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Carlino MS; Mohr P; De Galitiis F; Ross MI; Eroglu Z; Chen K; Jiang R; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Kirkwood JM
Eur J Cancer; 2022 Nov; 176():207-217. PubMed ID: 36202690
[TBL] [Abstract][Full Text] [Related]
35. Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany.
Engelhardt M; Ihorst G; Singh M; Rieth A; Saba G; Pellan M; Lebioda A
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e160-e175. PubMed ID: 33218965
[TBL] [Abstract][Full Text] [Related]
36. Normative data for the EORTC QLQ-C30 from the Austrian general population.
Lehmann J; Giesinger JM; Nolte S; Sztankay M; Wintner LM; Liegl G; Rose M; Holzner B;
Health Qual Life Outcomes; 2020 Aug; 18(1):275. PubMed ID: 32787854
[TBL] [Abstract][Full Text] [Related]
37. The relationship of changes in EORTC QLQ-C30 scores to ratings on the Subjective Significance Questionnaire in men with localized prostate cancer.
Rodrigues G; Bezjak A; Osoba D; Catton P; Tsuji D; Taylor D; Warde P
Qual Life Res; 2004 Sep; 13(7):1235-46. PubMed ID: 15473502
[TBL] [Abstract][Full Text] [Related]
38. Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients.
Grande GE; Farquhar MC; Barclay SI; Todd CJ
Palliat Support Care; 2009 Sep; 7(3):289-97. PubMed ID: 19788770
[TBL] [Abstract][Full Text] [Related]
39. Frailty is associated with decline in health-related quality of life of patients treated for head and neck cancer.
de Vries J; Bras L; Sidorenkov G; Festen S; Steenbakkers RJHM; Langendijk JA; Witjes MJH; van der Laan BFAM; de Bock GH; Halmos GB
Oral Oncol; 2020 Dec; 111():105020. PubMed ID: 33045628
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma.
Lordick F; Al-Batran SE; Ganguli A; Morlock R; Sahin U; Türeci Ö
Gastric Cancer; 2021 May; 24(3):721-730. PubMed ID: 33755863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
